A Long-term, Open-label Follow-up Study Of Tofacitinib For Treatment Of Juvenile Idiopathic Arthritis (Jia)

Trial Profile

A Long-term, Open-label Follow-up Study Of Tofacitinib For Treatment Of Juvenile Idiopathic Arthritis (Jia)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Sep 2017 Planned number of patients changed from 290 to 340.
    • 11 Sep 2017 Planned End Date changed from 21 Sep 2020 to 31 Mar 2021.
    • 11 Sep 2017 Planned primary completion date changed from 21 Sep 2020 to 31 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top